Lupimeg 1000mg Tablet contains Imeglimin, a novel oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus. Imeglimin acts through a unique dual mechanism by improving mitochondrial function and enhancing insulin sensitivity in peripheral tissues, thereby reducing hepatic glucose production and increasing glucose uptake. This pharmacological profile helps in achieving better glycemic control without significant risk of hypoglycemia when used as monotherapy or in combination with other antidiabetic agents. Lupimeg is typically prescribed as part of a comprehensive diabetes management plan, including diet and exercise. The recommended dosage is one 1000mg tablet taken orally once or twice daily, depending on the patient's glycemic status and physician’s discretion. Clinical trials have demonstrated that Imeglimin effectively lowers HbA1c levels and fasting plasma glucose with a favorable safety and tolerability profile. Common adverse effects are generally mild and may include gastrointestinal disturbances such as nausea or diarrhea. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Lupimeg should be used under medical supervision, with regular monitoring of blood glucose and renal function to optimize therapeutic outcomes and minimize potential risks.